cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
dwi rizki febrianti
Contact Email
dwirizkyfeby@gmail.com
Phone
+6285222400404
Journal Mail Official
jifi@stikes-isfi.ac.id
Editorial Address
Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin Jl. Flamboyan III/7C Kayu Tangi 70123 Banjarmasin Kalimantan Selatan Telepon: (0511)-3301610, 3300221 Email: jifi@stikes-isfi.ac.id
Location
Kota banjarmasin,
Kalimantan selatan
INDONESIA
Jurnal Insan Farmasi Indonesia
Published by Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin
ISSN : 26213184     EISSN : 26214032     DOI : https://doi.org/10.36387/jifi
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Medicine & Pharmacology Physics
Focus and Scope Jurnal Insan Farmasi Indonesia (JIFI) is a broad-based primary journal covering all branches of pharmacy and its sub-disciplines that contains complete research articles, short communication and review articles. JIFI is a forum for the publication of quality and original works that open discussions in the field of pharmacy and health sciences.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Ilmu Farmasi
Articles 314 Documents
 28   29   30   31   32 
STANDARISASI SIMPLISIA BAWANG DAYAK (Eleutherine bulbosa (Mill.) Urb) MELALUI ANALISIS PARAMETER SPESIFIK DAN NON-SPESIFIK Kaffah, Silmi; Silmi Kaffah; Moch. Saiful Bachri; Laela Hayu Nurani; Wahyu Widyaningsih; Muhammad Ma’ruf; Danang Prasetyaning Amukti
Jurnal Insan Farmasi Indonesia Vol 8 No 1 (2025): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jifi.v8i1.2520

Abstract

Bawang dayak (Eleutherine bulbosa (Mill.) Urb) merupakan bahan alami berupa serbuk kering yang diperoleh dari umbi tanaman ini. Standardisasi sangat penting untuk memastikan konsistensi kualitas, keamanan, dan kemanjuran bagi konsumen. Tujuan penelitian ini adalah untuk mengevaluasi mutu bawang dayak yang diperoleh dari kota Sintang, Kalimantan Barat berdasarkan uji parameter spesifik dan non spesifik. Pengujian dilakukan dengan mengukur parameter non spesifik dan parameter spesifik. Hasil uji parameter non spesifik menunjukkan bahwa Simplisia memiliki kadar air sebesar 9,10%, kadar abu total 0,57%, dan kadar sari larut etanol 5,46%, menunjukkan stabilitas dan kemurnian yang baik. Uji parameter spesifik menunjukkan bahwa kandungan flavonoid total adalah 3,57 mg QE/g dan kandungan fenolik total adalah 2,05 mg GAE/g, yang menunjukkan potensi kapasitas antioksidan dan aktivitas farmakologis. Penelitian ini dapat disimpulkan bahwa umbi bawang dayak memenuhi standar mutu berdasarkan uji parameter spesifik dan non spesifik, layak digunakan sebagai bahan baku obat herbal. Penelitian lebih lanjut diperlukan untuk mengoptimalkan penggunaannya dalam formulasi farmasi.
KESESUAIAN PENYIMPANAN OBAT HIGH ALERT DI INSTALASI FARMASI RUMAH SAKIT X BANJARMASIN Ilahi, Fitrah Shafran; Rahmah; Yumassik, Abdul Mahmud; Nordin; Ainah, Nur; Istiqamah, Farida; Faqih, Muhammad
Jurnal Insan Farmasi Indonesia Vol 8 No 1 (2025): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jifi.v8i1.2521

Abstract

High Alert is a type of drug that needs to be taken seriously as it can often lead to fatal errors and also has a high potential to trigger Adverse Drug Reactions. These drugs are divided into three categories, namely High Risk drugs, High Concentrate Electrolytes, and Look Alike Sound Alike/ Drug Name Look and Sound Similar. The purpose of this study was to assess the suitability of High Alert drug storage at the Banjarmasin X Hospital Pharmacy Installation based on the standard operating procedure for High Alert drug storage. The research method used qualitative observational with a cross-sectional approach. The study sample included 158 items of High Alert drugs in the Pharmacy Warehouse, Outpatient Pharmacy Depot, and Inpatient Pharmacy Depot, taken using the Total Sampling technique and data collected prospectively using a checklist sheet. Then processed with Microsoft Excel based on standard operating procedures. The results showed that the suitability of High Alert drug storage in the Pharmacy Warehouse was 99% (61 items), Outpatient Pharmacy Depot was 100% (41 items), and Inpatient Pharmacy Depot was 98% (51 items). Overall, the average suitability of High Alert drug storage in the three depots is 99% suitable in drug storage.
ANALISIS COST OF ILLNESS PASIEN DIABETES MELITUS DAN HIPERTENSI DI RSUD SULTAN SURIANSYAH Aisyah, Noor; Mahmud Yumassik, Abdul; Puteri Amalia, Senya; Raida; Muharromah, Siti
Jurnal Insan Farmasi Indonesia Vol 8 No 1 (2025): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jifi.v8i1.2325

Abstract

Diabetes melitus dan hipertensi merupakan penyakit kronis yang membutuhkan terapi rutin untuk mengontrol penyakitnya. Pembiayaan penyakit tersebut dapat diukur dengan analisis cost of illness yang merupakan analisis untuk mengukur beban ekonomi penyakit pada masyarakat. Hipertensi dan diabetes melitus prevalensinya terus meningkat serta biaya perawatan yang tinggi. Tujuan penelitian adalah untuk mengetahui rata-rata Cost of Illness (COI) pada pasien hipertensi dan diabetes melitus rawat jalan dan faktor karakteristik yang mempengaruhi. Metode penelitian menggunakan teknik accidental sampling berdasarkan pendekatan prosfektif dari kuesioner dan retrospektif menggunakan data administrasi rumah sakit tahun 2024. Penelitian dilakukan di RSUD Sultan Suriansyah Kota Banjarmasin pada pasien rawat jalan dengan jumlah sampel 82 pasien diabetes melitus dan 85 pasien hipertensi. Data dianalisis menggunakan Microsoft Excel. Hasil penelitian menunjukkan rata-rata biaya Cost of Illness pada pasien diabetes melitus perepisode perawatan yaitu Rp.208.652 dengan rata-rata biaya medis langsung sebesar Rp.149.446, biaya non medis langsung sebesar Rp.20.024 dan biaya tidak langsung sebesar Rp.39.181. Sedangkan rata-rata biaya pada pasien hipertensi selama perepisode perawatan yaitu Rp.168.449, rata-rata biaya medis langsung Rp.98.264, biaya non medis langsung Rp.16.811 dan biaya tidak langsung Rp.53.676.
PROFIL PENGGUNAAN CHOP DAN RCHOP PADA PASIEN LIMFOMA NON-HODGKIN DI RSUP DR. SARDJITO Gustinanda, Rizky; Irham, Lalu Muhammad; Supadmi, Woro; Khair, Riat El
Jurnal Insan Farmasi Indonesia Vol 8 No 1 (2025): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jifi.v8i1.2529

Abstract

Non-Hodgkin lymphoma (LNH) is a heterogeneous malignancy of the lymphatic system with CHOP and RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) chemotherapy regimens as main options. Local data on patient characteristics undergoing these treatments are still limited, especially at Dr. Sardjito General Hospital. This study evaluates the characteristics of LNH patients receiving both regimens at Dr. Sardjito (2020–2023). It is a descriptive observational study with a cross-sectional design. Data from patient medical records were analyzed descriptively. Of 176 patients, 80 received CHOP and 96 R-CHOP. Most were male (CHOP: 70%; R-CHOP: 60.4%) and aged >50 years, with peak age of 51–60 in CHOP (40%) and >60 in R-CHOP (44.8%). Comorbidities were found in one-third of patients. Advanced stage predominated (CHOP: 31.3% stage 4; R-CHOP: 38.5% stage 2), and most completed 6 chemotherapy cycles. Rituximab ≥550 mg was widely used in R-CHOP; cyclophosphamide >1100 mg, doxorubicin 70–79 mg, and vincristine ≥2 mg were standard in both regimens. Prednisone 100 mg was common. Diffuse Large B-Cell Lymphoma (DLBCL) dominated R-CHOP (98.96%), while CHOP patients included DLBCL (38.75%), FL, PTCL-NOS, and others. Findings highlight the importance of individualized treatment based on histopathology and disease stage.

Page 32 of 32 | Total Record : 314

 28   29   30   31   32 

Filter by Year

2018 2025


Reset
Filter By Issues
All Issue Vol 8 No 1 (2025): Jurnal Insan Farmasi Indonesia Vol 7 No 3 (2024): Jurnal Insan Farmasi Indonesia Vol 7 No 2 (2024): JIFI : Special edition Vol 7 No 1 (2024): Jurnal Insan Farmasi Indonesia Vol 6 No 2 (2023): Jurnal Insan Farmasi Indonesia Vol 6 No 1 (2023): Jurnal Insan Farmasi Indonesia 2023: JIFI: Webinar & call for paper Vol 5 No 2 (2022): Jurnal Insan Farmasi Indonesia Vol 5 No 1 (2022): Jurnal Insan Farmasi Indonesia Vol 4 No 2 (2021): Jurnal Insan Farmasi Indonesia Vol 4 No 1 (2021): Jurnal Insan Farmasi Indonesia Vol 3 No 2 (2020): Jurnal Insan Farmasi Indonesia Vol 3 No 1 (2020): Jurnal Insan Farmasi Indonesia Vol 2 No 2 (2019) Vol 2 No 1 (2019) Vol 1 No 2 (2018) Vol 1 No 1 (2018) More Issue